Supriya Lifesci. Q4FY26 Concall Decoded: Record Quarter, But Working Capital Days Hit 170
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1. Opening Hook
Supriya Lifescience walked into its earnings call with a record quarter: ₹277 crore revenue, up 50% YoY. The catch? Management casually mentioned geopolitical disruptions cost them ~₹10 crore that same quarter—meaning the headline number dodges an unstated counterfactual. EBITDA margin hit 35.5%, surpassing their own 33–35% guidance. But the real story lurking in the footnotes: working capital days ballooned to 170, up from 158 a year prior. All the growth in the world rings hollow if cash gets stuck in inventory and receivables.
2. At a Glance
Q4 Revenue: ₹277 cr – Record quarter, +50% YoY; ~₹10 cr headwind impact baked in.
“We received EIR with Voluntary Action Indicated; inspection covered 7 blocks, only one minor observation proactively addressed, reinforcing robust quality system and adherence to cGMP standards.”
Translation: The FDA found something minor, we fixed it before they officially asked. “Voluntary Action Indicated” is FDA-speak for “do better”—not a free pass, not a showstopper, just a footnote.
On margin outperformance:
“We’re surpassing our guided range of 33% to 35%.”
Translation: We beat our own target. Management then immediately reiterated the same 33–35% guidance for forward years.
On US market entry timing:
“The current portfolio inherently does not have a very large market in the U.S. Expect higher US relevance over 3–4 years as newer launches scale.”
Translation: We’re not in the US market now. Three to four years is industry-speak for “we’ll revisit this slide in 2029.”
On new product mix and margins:
“New products initially scale in semi-regulated markets at lower realizations, then mature into regulated markets over 2–3 years…we’re continuously adding 3–4 molecules/year.”
Translation: We launch cheap, let them ripen, then sell them dear. But we keep launching new cheap ones, so the blended margin never quite rips.
On the Patalganga capex behemoth:
“Need to be prepared for when these products scale…a lot of larger companies want to tie up with us for basket kind of products.”
Translation: CMOs are calling. We’re building factories now so we can say yes later.
On DSM/riboflavin scale-up:
“Volumes stabilized at ~3 tons/month; expected peak ~₹60 cr, very close in FY27.”
Translation: We’re halfway to the revenue peak. “Very close” in pharma is 9–15 months.
On GLP-1 semaglutide oral tablet:
“Formulation uses a different binding agent, better absorption vs current market; we’ve approached Novo.”
Translation: We think our version is better. Novo hasn’t replied—or has, but not on camera.
